Regulatory Stability in Drug Development

Publications Presentations

Patent Preparation Expert Witness

New Product Acquisition Drug Delivery Systems

Preformulation Formulation and Process Design Analytical Method Development and Validation Feasibility and Stability Quality By Design IND CMC Documentation Bioavailability Reverse Engineering of Pharmaceucial Formulation

Quality By Design Process Optimization Scale-Up and Clinical Manufacture Analytical Methods Regulatory Stability Process Validation Technical Transfer Bioequivalence Testing NDA CMC Documentation

Quality By Design for Excipients Excipient Safety Regulatory Alternate Sources Quality Management Systems

Excipients Drug Delivery Systems Clinical Trial Supplies Medicinal Products

Stability studies on both the API and the formulated product are required at all stages of clinical development. The expectation from the regulatory agencies is that a shelf-life sufficient to cover the use of the material in the intended clinical trial will be assigned, and that it can be justified based on scientific data.

Stability testing is an important part of any product regulatory submission. Stability data will be required on both the drug substance (API) and the formulation(s). The Guidance documents from ICH (International Conference on the Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) have standardized the data requirements in the three ICH regions (Europe, Japan and the United States). However, there are some exceptions, particularly for products intended for use in very hot and humid climates.

Regulatory stability usually refers to the formal stability studies in the eventual commercial container that will be used to support the shelf-life claim in the marketing application (viz. NDA in the US). The stability studies are required to be carried out using materials manufactured using the intended commercial process and greater than 1/10th the intended commercial scale.

FinnBrit Consulting has the experience to be able to advise clients on how to organize their regulatory stability programs.

All information published throughout www.finnbrit.com is intended for information only, and does not contain any warranties, implied or otherwise.

Site Map